New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:24 EDTABBV, MRK, IDIXAbbVie shares defended at BMO Capital
After Abbvie's (ABBV) stock fell following Merck's (MRK) acquisition of Idenix (IDIX), BMO Capital still believes that the size and durability of the HCV market and Abbvie's franchise are unappreciated. The firm sees Merck as a significant competitor in HCV, but adds that the potential of the assets it acquired from Idenix is "uncertain and somewhat risky." BMO Capital continues to identify AbbVie as a top pick.
News For ABBV;IDIX;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
07:07 EDTABBVBiogen, AbbVie say EMA validates MAA for Zinbryta for treatment of MS
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the companies’ Marketing Authorisation Application for ZINBRYTA for the treatment of relapsing forms of multiple sclerosis in the European Union. Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA’s Committee for Medicinal Products for Human Use. The MAA included results from two clinical trials, DECIDE and SELECT, in which ZINBRYTA 150 mg was administered subcutaneously every four weeks in people with relapsing-remitting MS. Biogen and AbbVie are jointly developing ZINBRYTA.
March 26, 2015
08:31 EDTMRKMerck announces collaboration with American Diabetes Association
Merck announced a collaboration with the American Diabetes Association. The collaboration aims to educate adults with diabetes about their increased risk for potentially serious health problems, including pneumococcal pneumonia, influenza and hepatitis B, making it important for people with Type 1 or Type 2 diabetes to talk to their health care professional about these diseases.
March 25, 2015
07:28 EDTMRKOptions expected to be active
Subscribe for More Information
March 24, 2015
19:40 EDTMRKOn The Fly: After Hours Movers
Subscribe for More Information
17:02 EDTMRKMerck announces new $10B share repurchase program
Merck announced that its board of directors has authorized additional purchases of up to $10B of Merck’s common stock for its treasury. The treasury stock purchase has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. With this announcement, the company’s total outstanding share repurchase authorization is now approximately $11.7B, which includes approximately $1.7B in authorized repurchases remaining under the program previously announced on May 1, 2013. Merck continues to expect average diluted shares outstanding will be approximately 2.86B in 2015.
17:00 EDTMRKMerck announces new $10B share repurchase program
Subscribe for More Information
16:00 EDTMRKOptions Update; March 24, 2015
iPath S&P 500 VIX Short-Term Futures down 10c to 25.14 Option volume leaders: AAPL TSLA TWTR GILD FB AMAT GOOG C MRK GILD according to Track Data.
08:31 EDTMRKMerck: Phase 3 KEYNOTE-006 study met co-primary endpoints, will be stopped early
Subscribe for More Information
March 23, 2015
09:45 EDTMRKUBS to hold a field trip
Subscribe for More Information
09:03 EDTABBVLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:17 EDTABBV, MRKAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
07:41 EDTMRK, ABBVAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
08:47 EDTABBVAbbVie and C2N sign worlwide license agreement for Alzheimer's Disease therapy
AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. Financial terms of the collaboration were not disclosed.
07:56 EDTABBVAbbVie plans $30M expansion at plant in Puerto Rico, AP reports
AbbVie is planning to expand one of its facilities in Barceloneta, Puerto Rico, The Associated Press reports. The $30M expansion is slated for a plant that manufactures products related to immunology, virology and metabolic disorders. Reference Link
March 17, 2015
08:03 EDTABBVAbbVie to present data from 22 HUMIRA abstracts at AAD
Subscribe for More Information
06:31 EDTABBVStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
March 16, 2015
15:33 EDTMRKMerck says study shows VYTORIN reduced CV events more than simvastatin alone
Subscribe for More Information
15:04 EDTABBVPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use